AURN001 Achieves Dose-Dependent Response at 6 Months, With Zaina Al-Mohtaseb, MD

Published Date: 10 May 2025

A Phase 1/2 trial shows promising results for corneal edema, highlighting significant visual and quality of life improvements with an innovative cell therapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast density changes over time are associated with an increased risk of cancer.

2.

How the metastasis of cancer is driven by cellular plasticity.

3.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

4.

Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer

5.

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot